Entries by admin

A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies?

/in /by

A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies? Henry Danahay1, Clive McCarthy1 and Martin Gosling1 1Enterprise Therapeutics, UK Objectives: Recent clinical studies with ENaC modulator compounds have challenged the validity of the target for treating CF lung disease. Our aim was to establish […]

The pharmacology of novel TMEM16A potentiator compounds

/in /by

The pharmacology of novel TMEM16A potentiator compounds Henry Danahay1,2, Sarah Lilley1, Holly Charlton1, Roy Fox1, Brian Button3, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North Carolina, Chapel Hill, USA TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium […]

EACT increases intracellular calcium levels by a TMEM16A-independent mechanism

/in /by

EACT increases intracellular calcium levels by a TMEM16A-independent mechanism Sarah Lilley1, Henry Danahay1,2, Holly Charlton1, Kathryn Adley1, Roy Fox1, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK The N-aroylaminothiazole EACT was first described by Namkung et al. (2011) as an activator of the calcium-activated chloride channel, TMEM16A. Subsequently, EACT has been used as […]

Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman

/in /by

Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK, 25 March 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the appointment of Amit […]

Gordon Research Conference ‘Modeling and Targeting Mucociliary Function in Health and Disease: Genes to Cells to Interaction Networks and Tissues’ February 2019

/in /by

Identifying pathways & compounds regulating goblet cell metaplasia in vitro Henry Danahay1, Roy Fox2 and Martin Gosling1 1Enterprise Therapeutics, UK; 2University of Sussex, UK It is widely accepted that the composition of mucus in the CF airway, and the hydration status, significantly affects its clearance and thereby the potential for form plugs, restrict airflow and […]

Enterprise Therapeutics selected as a finalist for Scrip Awards and Lifestars Awards

/in /by

Scrip Awards 2018 “Financing Deal of the Year- Private” category Lifestars Awards 2018 “EU Private Finance Raise of the Year <£30M” category Brighton, UK – 02 October 2018: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has recently been announced as […]

32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 210

/in /by

Submission: 210 – PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE OF A NOVEL INHALED ENAC BLOCKER, ETD001   Henry Danahay1, Clive McCarthy1, William Abraham2, Holly Charlton3, Sarah Lilley3, Roy Fox3 and Martin Gosling1 1Enterprise Therapeutics, UK; 2Mount Sinai Medical Center, USA; 3University of Sussex, UK   Inhaled drugs are typically cleared very rapidly from the airway mucosa. Inhaled […]

32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 89

/in /by

Submission: 89 – IDENTIFYING PATHWAYS REGULATING GOBLET CELL METAPLASIA: PHENOTYPIC SCREENING WITH BRONCHOSPHERES Henry Danahay1, Clive McCarthy1, Roy Fox2 and Martin Gosling1 1Enterprise Therapeutics, UK; 2University of Sussex, UK   The composition of mucus in the CF airway, and in particular the hydration status, significantly affects its clearance and thereby the potential for form plugs, […]

Enterprise Therapeutics raises £29 million ($41 million USD) funding

/in /by

Brighton, UK – 12 April 2018: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed an oversubscribed £29 million ($41 million USD) Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also […]